Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management
The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the ...
Verywell Health on MSN2d
7 Common Causes of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
Medical Xpress27d
Modifying macrophages in the lung could head off pulmonary hypertension
As more infants survive premature births and develop bronchopulmonary dysplasia (BPD), a chronic lung disease, more are developing pulmonary hypertension. It's believed that BPD arrests the ...
The American Journal of Managed Care4d
PAH Therapies Improve Outcomes in PH-ILD
Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...
New program for patients suffering from pulmonary hypertension
A new program in the Central Valley is now offering much-needed treatments for patients suffering from an advanced form of lung disease called pulmonary ...
Business Post7h
ATXA’s journey to trial a new lung disease treatment enters critical phase
ATXA Therapeutics, a Dublin-based pharmaceuticals business, expects to start the first trials with patients of its lung and ...
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA
Liquidia (LQDA) announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for YUTREPIA inhalation ...
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...